MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced its participation in the 2025 BIO International Convention, held from June 16-19 at the Boston Convention & Exhibition Center. The biopharmaceutical company will highlight its novel modifier gene therapy platform, designed as a potential one-time treatment for major blindness diseases, while exploring new partnership opportunities.
During the convention, Ocugen’s leadership will meet with pharmaceutical executives and potential collaborators to further the development and commercialization of its cutting-edge therapies. A key focus will be on OCU400, the company’s lead candidate targeting inherited retinal diseases.
“We are excited to return to BIO this year on the heels of our recent partnership in Korea for exclusive rights to OCU400,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “This regional collaboration is just the beginning. BIO provides the perfect platform to build on our momentum and engage with industry leaders to propel our first-in-class gene therapies forward, creating value for patients and shareholders alike.”
Ocugen has hit several critical milestones over the past year. These include alignment with the FDA for the Phase 2/3 pivotal confirmatory trial and the Rare Pediatric Disease Designation for OCU410ST. Additionally, enrollment is nearing completion for the Phase 3 liMeliGhT clinical trial for OCU400, with a Biologics License Application (BLA) submission expected by mid-2026.
Dr. Musunuri is scheduled to deliver a company presentation and participate in two panel discussions during the convention, including the Longwood Healthcare Leaders MIT CEO Conference.
Presentation and Panel Discussion Details
Company Presentation
- Date: Monday, June 16, 2025
- Time: 4 p.m. EDT
- Location: Room 153A
Panel Discussion
- Topic: Optimizing Your Clinical Program Outcomes: Creating an Evidence-Based Value Proposition for Commercial Success
- Date: Wednesday, June 18, 2025
- Time: 9-10 a.m. EDT
- Location: Room 258A
Longwood Healthcare Leaders MIT CEO Conference Panel
- Topic: Navigating the Regulatory Landscape
- Date: Tuesday, June 17, 2025
- Time: 3-3:30 p.m. EDT
- Location: Koch Institute, Massachusetts Institute of Technology
Ocugen’s participation underscores its commitment to advancing next-generation treatments for blindness diseases while driving progress in the gene therapy sector. With recent achievements and strategic initiatives, the company is poised to capture the attention of its peers at this premier industry event.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.